Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg vs Placebo in People With Obesity and Prediabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Lancet Diabetes Endocrinol 2024 Jul 29;[EPub Ahead of Print], BM McGowan, JM Bruun, M Capehorn, SD Pedersen, KH Pietiläinen, HAK Muniraju, M Quiroga, A Varbo, DCW LauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.